Bestan Plus Tablets
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
MFDS item code 200710805 · Notified 2007.09.27
This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension
This medication is used to control blood pressure in patients with essential hypertension. It is also effective in cases where blood pressure is not sufficiently controlled with monotherapy. Additionally, it is used as an initial treatment in moderate to severe hypertension patients who require combination therapy to reach target blood pressure. Thus, it plays a crucial role in blood pressure management and helps prevent complications due to hypertension.
This medicine is administered once daily, regardless of meals. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If needed, this medicine may be administered concomitantly with other antihypertensive agents. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, target blood pressure, and the expected increase in the likelihood of achieving the treatment target compared with monotherapy. Treatment is generally initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily, and the dose may be increased after 1 ~ 2 weeks, up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg, if blood pressure control is needed. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is required in patients with renal impairment and creatinine clearance of 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, the imbalance should be corrected before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is required for patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is required for older adults.
Children and adolescents under 18 years of age: The safety and efficacy of this medicine have not been established.
This medication can cause serious damage to the fetus or newborn if used during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Women who are pregnant or breastfeeding, and patients allergic to any components of this medication or with certain kidney dysfunction should not use this medication. Patients with severely impaired kidney function or anuria should also avoid this medication. Patients with hypotension or problems with renal vasculature, patients with impaired liver function, and patients with heart valve diseases should use this medication cautiously. The Hydrochlorothiazide component may react sensitively to sunlight, increasing the risk of skin cancer, so UV protection and monitoring of skin condition are necessary during treatment. Common side effects may include dizziness, fatigue, nausea, and vomiting, and regular blood tests are necessary as kidney function indicators or electrolyte levels may change. This medication does not significantly affect driving or machine operation abilities, but caution is advised due to possible dizziness or fatigue. Electrolyte imbalances such as sodium and potassium levels may occur during treatment; these should be periodically checked through blood tests. Particularly, it is essential to monitor potassium levels to ensure they do not become too high or low, and extra caution is necessary when using potassium supplements or potassium-depleting agents. This medication can be used in combination with other antihypertensives, but it is advisable not to use it with lithium preparations. The combination with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the blood pressure control effect, so consultation with a healthcare professional is required. There is a risk to fetal health during pregnancy, so it is imperative to consult a physician if planning pregnancy or if pregnant, and it is safe not to use this medication while breastfeeding. Safety in children and adolescents has not been established, so it is not recommended. Special caution is required for the elderly, as they may be more sensitive to bodily responses. In case of overdose, symptoms such as hypotension, electrolyte abnormalities, and dehydration may occur, thus immediate medical attention is necessary for appropriate treatment. This medication should be stored out of reach of children and kept sealed in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to prevent exposure to air and moisture. It is best kept at room temperature between 1 to 30 degrees Celsius.
Pink, biconvex, rectangular film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationIrbesartan 300mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
Irbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Myungin Pharmaceutical Co., Ltd.
CombinationIrbesartan 300mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Myungin Pharmaceutical Co., Ltd.
CombinationIrbesartan 150mg · Hydrochlorothiazide 12.5mg
Tablet · Prescription medication · Combination
Ahn-Guk Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.